NCT07068646

Brief Summary

This is a prospective, multicenter, randomized controlled trial comparing CT-guided versus empirical pulsed field ablation (PFA) for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. The study investigates whether atrial wall thickness-based energy titration improves arrhythmia outcomes compared to standard empirical ablation using the PulseSelect™ system.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
298

participants targeted

Target at P50-P75 for not_applicable atrial-fibrillation

Timeline
39mo left

Started Aug 2025

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress20%
Aug 2025Jul 2029

First Submitted

Initial submission to the registry

July 7, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 16, 2025

Completed
16 days until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2029

Last Updated

July 16, 2025

Status Verified

July 1, 2025

Enrollment Period

4 years

First QC Date

July 7, 2025

Last Update Submit

July 7, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Freedom from atrial arrhythmia recurrence

    Any documented episode of AF, atrial flutter, or atrial tachycardia lasting ≥30 seconds after a 3-month blanking period.

    Within 1 year after 3 months of procedure

Secondary Outcomes (1)

  • Procedure-related cardiac complication rate

    30 days after procedure

Study Arms (2)

CT myocardial thickness map guided PV isolation group

EXPERIMENTAL
Procedure: CT myocardial thickness map guided PV isolation group

Empirical PV isolation group

ACTIVE COMPARATOR
Procedure: Empirical PV isolation group

Interventions

Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system. A pre-procedural cardiac CT scan will be used to generate an atrial myocardial thickness map. In this group, atrial segments with wall thickness \>2.5 mm identified on the CT map will receive additional PFA applications (up to 8 per PV) to ensure transmural lesion formation. All other segments will receive the standard minimum of 8 applications per vein. The ablation catheter will remain stationary to allow lesion stacking when needed.

CT myocardial thickness map guided PV isolation group

Pulmonary vein isolation will be performed using the PulseSelect™ pulsed field ablation system according to a standardized empirical protocol. Each pulmonary vein will receive a minimum of 8 PFA applications without adjustment based on anatomical or CT-based parameters. Additional applications may be delivered at the operator's discretion based on procedural findings, but no wall thickness mapping will be used.

Empirical PV isolation group

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Patients with persistent or permanent atrial fibrillation
  • Atrial fibrillation associated with severe cardiac malformation or a structural heart disease that is hemodynamically affected
  • Patients with severe renal impairment or CT imaging difficulty using contrast media
  • Patients with a past history of radiofrequency ablation for atrial fibrillation or other cardiac surgery
  • Patients with active internal bleeding
  • Patients with contraindications for anticoagulation therapy(for prevention of cerebral infarction) and antiarrhythmic drugs
  • Patients with valvular atrial fibrillation (mitral stenosis \>grade 2, mechanical valve, mitral valvuloplasty)
  • Patients with a severe comorbid disease
  • Expected survival \< 1 year
  • Drug addicts or alcoholics
  • Patients who cannot read the consent form (illiterates, foreigners, etc.)
  • Other patients who are judged by the principal or sub-investigator to be ineligible for participation in this clinical study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Severance Hospital

Seoul, 120-752, South Korea

Location

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 7, 2025

First Posted

July 16, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

July 31, 2029

Study Completion (Estimated)

July 31, 2029

Last Updated

July 16, 2025

Record last verified: 2025-07

Locations